Contact us
Please fill out the details below and we will get back to you shortly.
Thank you!
We will be contacting you soon..
Close
We will be contacting you soon..
Oops! Something went wrong while submitting the form.
November 2024, Cambridge, MA – Seasoned drug delivery executive, Steven Kaufman, to join Portal Instruments as their Chief Commercial Officer. Prior to joining Portal Instruments in November 2024, Steven held executive positions at Stevanato Group, Bespak and SHL Medical.
November, 2024 Cambridge, MA – Portal Instruments is pleased to announce that Steven Kaufman will be joining Portal Instruments as their interim Chief Commercial Officer.
Steven is a recognized leader in the device industry, having held numerous leadership roles related to Business Development, Product Management, Marketing and Strategy. Prior to joining Portal Instruments in November 2024, Steven held executive positions at Stevanato Group, Bespak and SHL Medical.
Patrick Anquetil, CEO, welcomed Steven, noting Steven's broad expertise in the area of self-injection devices and his proven track-record taking devices from design, development, manufacture, final assembly to clinical and then commercial launch in Europe, North America and APAC. "Steven's expertise in drug delivery will be a strong asset to Portal Instruments as we continue to move towards commercialization."
September 2021 - Patrick Anquetil sat down with ASAP Biopharma ahead of his keynote "Alliance Managers Are Bringing Digital Health Innovation" which is slated for 10:20 a.m. EDT on September 28th. The keynote will be followed by a Q&A session.
January 18, 2022 - Despite recent innovations, like the launch in Europe of the first electromechanical reusable and connected auto-injector (UCB’s CIMZIA ava Connect® in early 2021), almost all new biologic drugs are launched with specific and undifferentiated self-injection options...
September 28, 2021 - Cambridge, MA Portal Instruments, developer of the PRIME needle-free drug delivery platform, announced that a new clinical study demonstrating patient preference for PRIME needle-free injections was published this month in the journal Drug Delivery.
Please fill out the details below and we will get back to you shortly.